Against GlaxoSmithKline’s objections, former head of the Food and Drug Administration David Kessler will be allowed to testify in front of a jury as an expert for the plaintiffs in a class action suit against the company.
London-based drug giant GSK violated antitrust laws when it filed "sham" petitions to the FDA in an effort to stall generic versions of its popular nasal spray, Flonase, from entering the market, third-party purchasers and generic drugmakers allege.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
